NEW Declaration of Helsinki 2024
The evolution of ethical standards in clinical research
from the Nuremberg Code to a new era
Before 1964, the landscape of medical research was a chaotic and often dangerous territory with minimal guidelines to protect patients’ rights and safety. This all changed when the World Medical Association (WMA) adopted the Declaration of Helsinki, establishing a set of ethical principles that have guided medical research for decades. Now, in 2024, we witness the latest revision of this landmark document, reflecting the ever-evolving landscape of medical research ethics.
The Declaration of Helsinki 2024 did not emerge in a vacuum. It is the eighth revision of a document whose roots stretch back to the aftermath of World War II — to the Nuremberg Code of 1947, through the Belmont Report of 1979, and onward to the ICH GCP guidelines that govern clinical trials worldwide today. Understanding the Declaration of Helsinki means understanding the entire ethical lineage that protects every research participant enrolled in a clinical trial.
The Declaration of Helsinki has been a guiding light in the realm of clinical research, ensuring that participants’ rights, safety, and wellbeing are always at the forefront. This latest update underscores the continued commitment to ethical principles in response to the dynamic nature of medical research.
If you work in good clinical practice, study ICH GCP training, or are preparing for a Good Clinical Practice certification, this guide will give you the complete historical context and a clear analysis of every key change introduced in the 2024 revision.
What is the Declaration of Helsinki?
The Declaration of Helsinki is a set of ethical principles for medical research involving human participants. It serves as a cornerstone for ensuring that the rights, safety, and well-being of research participants are protected. The Declaration of Helsinki has undergone several revisions since its inception, with the most recent update in 2024 marking a significant milestone.
The document was born out of a necessity to address the ethical dilemmas posed by modern medical research. Initially adopted in 1964, the Declaration of Helsinki has been revised multiple times to incorporate new ethical challenges and scientific advancements. It provides a framework for researchers worldwide, emphasizing the importance of ethical considerations in clinical trials.
In practical terms, the Declaration of Helsinki is not a legal instrument; no government is formally bound by it, but it has become the single most widely cited ethical reference in clinical research globally. Its principles are embedded in the ICH GCP guidelines, national regulations, and institutional review board (IRB) / independent ethics committee (IEC) standards across more than 60 countries.
The historical thread: Nuremberg Code, Belmont Report, Helsinki, and ICH GCP
To fully appreciate why the Declaration of Helsinki 2024 matters, it is essential to understand the historical thread from which it descends. The ethical standards governing clinical trials today did not appear suddenly; they were forged, one crisis at a time, over more than seven decades.
The Nuremberg Code (1947): the first ethical framework for clinical research
The starting point is 1947. Following the atrocities of Nazi Germany, where physicians conducted brutal experiments on concentration camp prisoners without consent or ethical oversight, the Nuremberg Doctors’ Trials produced what became known as the Nuremberg Code. This ten-point document was the first international articulation of the principle that voluntary informed consent is an absolute, non-negotiable requirement for human research participation.
The Nuremberg Code established several principles that remain directly traceable in modern ICH GCP E6 R3 requirements: the necessity of prior animal studies, the proportionality of risk to benefit, the right of the participant to withdraw at any time, and the responsibility of the qualified investigator to terminate the experiment if it is likely to cause harm. Despite its moral force, the Nuremberg Code was never formally adopted as binding law by any government, and its principles were not systematically applied to research programs in democratic countries. That gap is precisely what made the next step necessary.
What did the Belmont Report do? Understanding its 1979 purpose
The direct cause of the Belmont Report was an American scandal: the Tuskegee Syphilis Study, in which the United States Public Health Service deliberately withheld effective treatment from 399 Black men with syphilis for four decades, without their knowledge or genuine consent. When the study became public in 1972, the outrage prompted the United States Congress to pass the National Research Act of 1974, which created the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.
The Commission published the Belmont Report in 1979. Its purpose was both retrospective and prospective: to explain why the Tuskegee study was wrong, to identify the underlying ethical principles that had been violated, and to embed those principles into every future research endeavour. This is the 1979 purpose of the Belmont Report — not to create rules, but to identify the moral foundations from which all ethical research rules should derive.
The Belmont Report also clarified an important distinction that is still fundamental in Good Clinical Practice training today: the difference between medical practice and medical research, and why the protections applicable to one cannot simply be assumed to apply to the other.
What are the 3 principles of the Belmont Report?
The three principles of the Belmont Report are the philosophical foundation on which every ethical requirement in clinical research, including the Declaration of Helsinki and ICH GCP, ultimately rests. They are:
- Respect for persons: Individuals must be treated as autonomous agents. They must voluntarily enter research with adequate, genuine information. Those with diminished autonomy, children, prisoners, and cognitively impaired individuals require additional protections. In practice, this principle is what gives informed consent its ethical weight.
- Beneficence: Researchers have an obligation not only to do no harm (non-maleficence) but to actively maximize benefits and minimize harm. This principle underlies the risk–benefit assessment that is central to protocol review by IRBs and IECs.
- Justice: The benefits and burdens of research must be distributed fairly. No group should bear a disproportionate burden of research risk while another group reaps the benefits. The Tuskegee study was a textbook violation of the principle of justice. This principle is also what drives the emphasis on equitable participant selection and global research equity in the Declaration of Helsinki 2024.
These three Belmont Report principles are not abstract concepts. Every requirement you encounter in ICH GCP E6 R3 — from sponsor responsibilities and investigator obligations to informed consent procedures and independent ethics committee review — can be traced directly back to one or more of these three principles. This is why the Belmont Report is described as the ethical foundation of modern clinical research, and why understanding it is a core component of any credible GCP certification.
From the Belmont Report to the Declaration of Helsinki and ICH GCP
The relationship between these three frameworks is often misunderstood. They are not competing documents; they are complementary layers of the same ethical architecture.
The Belmont Report provides the philosophical framework — three broad principles from which all specific research ethics requirements can be derived. The Declaration of Helsinki provides a more detailed set of practical standards addressed specifically to physicians conducting medical research: requirements for ethics committee review, informed consent, trial registration, and data publication. The ICH GCP guidelines operationalize these principles into concrete procedural requirements for sponsors, investigators, monitors, and regulators worldwide.
ICH GCP E6 R3 explicitly states in its opening principles that clinical trials shall be conducted in accordance with the ethical principles originating in the Declaration of Helsinki. That makes the entire edifice of GCP compliance, every SOP, every monitoring visit, every audit trail, ethically grounded in a lineage that runs directly from Nuremberg through the Belmont Report to Helsinki and into current practice.
“Clinical trials should be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki.” — ICH GCP E6 (R3), Principle 1
Origins and key principles of the Declaration of Helsinki
The Declaration of Helsinki was first adopted in Helsinki, Finland, in 1964, inspired by the Nuremberg Code of 1947. It was the World Medical Association’s response to a gap in the Nuremberg Code: while the Code addressed medical experimentation, it was not designed specifically for physician-investigators or for the emerging reality of sponsored clinical drug research. The Declaration of Helsinki filled that gap.
Its key principles include respect for persons, beneficence, and justice, the same three principles later formalized in the Belmont Report. This is not a coincidence: both documents emerged from the same moral tradition, and the drafters of the Belmont Report were explicitly aware of the Declaration of Helsinki as a predecessor framework. These principles guide researchers in conducting ethical studies and safeguarding participants’ rights.
- Respect for persons: This principle emphasizes the need for informed consent and the protection of vulnerable populations. Participants must be fully aware of the nature of the research and voluntarily agree to participate.
- Beneficence: Researchers must ensure that the benefits of the research outweigh any potential risks. This involves minimizing harm and maximizing the potential benefits for participants and society.
- Justice: This principle focuses on the fair distribution of the benefits and burdens of research. It ensures that no group of people is unfairly burdened or excluded from the potential benefits of research.
Since 1964, the Declaration of Helsinki has been revised eight times: in 1975, 1983, 1989, 1996, 2000, 2008, 2013, and most recently in 2024. Each revision has responded to a new challenge: the emergence of placebo-controlled trials, the need for post-study access to treatments, the growing complexity of data privacy, and now, in 2024, the urgent demands of global equity and scientific integrity.
Importance of the Declaration of Helsinki in clinical research
The Declaration of Helsinki is crucial in clinical research as it provides a framework for ethical conduct. It ensures that research is conducted with integrity, transparency, and respect for participants. This is essential for maintaining public trust in the research enterprise and advancing scientific knowledge responsibly.
Ethical guidelines like the Declaration of Helsinki are vital for ensuring that research practices evolve alongside scientific advancements. They provide a moral compass for researchers, guiding them in conducting studies that respect human dignity and promote the greater good.
From a regulatory standpoint, the Declaration of Helsinki is referenced as the ethical foundation of ICH GCP, the international standard that governs Good Clinical Practice training, sponsor oversight, investigator responsibilities, and data integrity across all major regulatory markets. Without a solid understanding of the Declaration of Helsinki, it is impossible to fully understand why GCP requirements exist in the form they do.
Lessons from R3 audits: when Helsinki principles meet real-world practice
In our experience conducting audits across clinical trial sites, the provisions of the Declaration of Helsinki are not abstract principles; they surface as very concrete, auditable findings. Three patterns appear with particular consistency.
Informed consent and respect for persons. At sites with high subject turnover, auditors frequently identify informed consent forms that are signed without adequate time for the participant to read and consider the information. The Declaration of Helsinki requires that sufficient time be given for this decision. When pressed during audit interviews, site staff often reveal that the pressure to enroll quickly overrides the ethical requirement for genuinely voluntary, informed participation. This is a direct violation of the “respect for persons” principle, and a recurrent finding that a strong ICH GCP training program should specifically address.
Vulnerable populations and the 2024 update. The 2024 revision of the Declaration of Helsinki reframes how vulnerable populations are to be approached: rather than simply excluding them from research for their protection, the new language calls for their inclusion with appropriate safeguards. In audit observations, sites that rely on overly broad exclusion criteria for vulnerable groups may now find themselves out of step with current ethical expectations. The shift in language, from protecting populations from research to protecting them through research, is subtle but has direct implications for protocol design and IRB review.
Transparency and conflict-of-interest disclosure. The 2024 revision places explicit new requirements on transparency and the disclosure of conflicts of interest. Audit findings at sponsored sites frequently identify undisclosed financial relationships between investigators and sponsors. The new Declaration of Helsinki language on this point is unambiguous, and it is likely to be reflected in forthcoming ICH GCP E6 R3 implementation guidance. Sites preparing for audits would be well advised to review and update their conflict-of-interest policies now.
Rationale behind the new Declaration of Helsinki 2024
The 2024 Declaration of Helsinki revision was driven by the need to address contemporary ethical challenges and ensure the document’s continued relevance. The revision process spanned 30 months and involved extensive international consultation. The new version emphasizes responsible inclusion, transparency, and global justice in research.
The decision to update the Declaration of Helsinki was not taken lightly. A dedicated workgroup from 19 countries, input from 110 partners, and eight regional and topical meetings contributed to a comprehensive review. The result is a document that better reflects the complexities of modern clinical research and the need for rigorous ethical standards.
The 2024 revision also responds directly to concerns raised in the academic and regulatory communities about research practices in low- and middle-income countries (LMICs), where participants often bear the risks of research whose benefits flow primarily to wealthier nations. This global justice dimension is a significant philosophical expansion of the Declaration of Helsinki beyond its 2013 version — and it resonates directly with the third Belmont Report principle: justice.
Main differences between the 2013 and 2024 Declaration of Helsinki
To clearly understand the evolution of the Declaration of Helsinki, let’s look at a detailed comparison between the 2013 and 2024 versions:
- Protection for vulnerable populations: The 2013 version provided basic safeguards for vulnerable populations, whereas the 2024 version includes enhanced protections with specific guidelines for various vulnerable groups. Importantly, the 2024 Declaration of Helsinki reframes vulnerability as a context-dependent and dynamic characteristic, not a fixed status, a nuance with significant practical implications for protocol design.
- Transparency in clinical trials: Transparency in clinical trials has also been significantly improved in the 2024 update, which includes detailed protocols for reporting results and conflicts of interest. The requirement to register all clinical trials on a publicly accessible database before recruitment begins, and to publish results regardless of outcome, is now stated with greater clarity and force than in any previous version of the Declaration of Helsinki.
- Global justice and equity: While the 2013 version had general principles focusing on fairness, the new version has stronger commitments to equity, addressing global disparities in research participation and benefits. This is a direct response to documented patterns of extractive research, trials conducted in LMICs where the resulting products become unaffordable to the populations that bore the research burden.
- Community engagement: In the previous version, this was encouraged but not explicitly required. The updated Declaration of Helsinki now requires community engagement, emphasizing collaboration with participant communities in the design and conduct of research.
- Informed consent: The informed consent process has been enhanced to provide more comprehensive information to participants, including potential risks and benefits. The 2024 version also addresses the specific challenges of obtaining meaningful informed consent in digital and decentralized trial environments, a gap that was not present in 2013 but is increasingly relevant to modern trial designs.
- Scientific integrity: This is an entirely new provision in the Declaration of Helsinki 2024. The document now includes an explicit, zero-tolerance stance on research misconduct. All individuals, teams, and organizations involved in medical research are prohibited from engaging in scientific misconduct, fabrication, falsification, plagiarism, and undisclosed conflicts of interest. This provision aligns the Declaration of Helsinki with WHO best practices and reflects growing concern about data integrity in the global research ecosystem.
- Language and terminology: Finally, the language has been updated from participant-centered terminology to more inclusive, replacing “subjects” with “participants” to better respect their rights and agency.
Comparison: Declaration of Helsinki vs. Belmont Report vs. ICH GCP
For clinical research professionals preparing for a Good Clinical Practice certification, it is useful to understand how these three foundational frameworks relate to each other:
| Feature | Belmont Report (1979) | Declaration of Helsinki (2024) | ICH GCP E6 R3 (2025) |
|---|---|---|---|
| Origin | US National Commission; HHS | World Medical Association | International Council for Harmonisation |
| Scope | All human subjects research | Medical research involving humans | Interventional clinical trials |
| Nature | Ethical framework (principles) | Ethical principles + practical standards | Operational guideline (binding in many markets) |
| Core content | 3 principles: respect, beneficence, justice | 37 paragraphs across 8 revisions | Sponsor, investigator & site requirements |
| Key focus 2024/2025 | N/A (not revised) | Scientific integrity, global equity, vulnerability | Data integrity, decentralized trials, risk-based monitoring |
| Relationship to GCP | Ethical foundation | Explicitly referenced in ICH GCP Principle 1 | Operationalizes Helsinki and Belmont principles |
Key takeaways: Declaration of Helsinki 2024
- The Declaration of Helsinki 2024 is the eighth revision of the foundational ethical document for medical research, first adopted in Helsinki in 1964.
- It descends from a clear ethical lineage: Nuremberg Code (1947) → Declaration of Helsinki (1964) → Belmont Report (1979) → ICH GCP (1996 → R3, 2025).
- The three principles of the Belmont Report, respect for persons, beneficence, and justice, are the philosophical foundation of the Declaration of Helsinki and, by extension, of all ICH GCP requirements.
- The 2024 revision introduces six major advances: enhanced protection of vulnerable populations, strengthened transparency, global equity requirements, mandatory community engagement, improved informed consent provisions, and a new zero-tolerance policy on scientific misconduct.
- The 2024 version is the only official version; all previous versions have been replaced and should not be cited except for historical purposes.
- For clinical research professionals, understanding the Declaration of Helsinki is not optional: ICH GCP E6 R3 explicitly grounds its first principle in the ethical framework of the Declaration of Helsinki.
- Audit findings consistently show that violations of Declaration of Helsinki principles, inadequate informed consent, undisclosed conflicts of interest, exclusion of vulnerable populations, remain among the most common deficiencies at clinical trial sites.
Conclusion
The Declaration of Helsinki 2024 represents a significant step forward in the ethical conduct of medical research. By addressing contemporary challenges and reinforcing key principles, the new version ensures that research remains ethical, transparent, and just. As we move forward, it is essential to uphold these standards to maintain public trust and advance scientific knowledge responsibly.
Ethical research is a shared responsibility that requires continuous vigilance and adaptation. The 2024 revision of the Declaration of Helsinki underscores the importance of this commitment and provides a robust framework for ethical clinical research in the modern era. The current version (2024) is the only official one; all previous versions have been replaced and should not be used or cited except for historical purposes.
What makes the 2024 revision particularly significant is its explicit acknowledgment that ethics in clinical research is not a static standard. The same moral lineage that ran from the Nuremberg Code through the Belmont Report and the Declaration of Helsinki into ICH GCP will continue to evolve. Clinical research professionals who understand this history, and who ground their practice in the three Belmont Report principles of respect, beneficence, and justice, will be best placed to navigate whatever challenges come next.
Ready to master the ethical foundations of clinical research?
The Declaration of Helsinki 2024, the Belmont Report, and ICH GCP E6 R3 are all core components of our Good Clinical Practice certification training. Whether you are new to clinical research or preparing for a compliance audit, our ICH GCP training course gives you the knowledge and credentials you need, recognized globally and designed for working professionals. Enroll today →
FAQ: Declaration of Helsinki
What is the Declaration of Helsinki 2024?
The Declaration of Helsinki 2024 is the eighth revision of the World Medical Association’s foundational ethical framework for medical research involving human participants. First adopted in 1964, it establishes the ethical principles, informed consent, ethics committee review, risk–benefit assessment, transparency, and global equity, that underpin all modern clinical research standards, including the ICH GCP guidelines. The 2024 version is the only currently valid version; all previous versions have been replaced.
What are the 3 principles of the Belmont Report, and how do they relate to the Declaration of Helsinki?
The three principles of the Belmont Report are respect for persons, beneficence, and justice. They are the ethical foundation of the Declaration of Helsinki and, through it, of ICH GCP. Respect for persons underlies informed consent requirements. Beneficence drives risk–benefit assessment. Justice governs participant selection and, in the 2024 Declaration of Helsinki, global equity in research. The two documents are complementary: the Belmont Report provides the philosophical framework; the Declaration of Helsinki translates that framework into practical standards for medical researchers.
What did the Belmont Report do?
The Belmont Report (1979) established the three ethical principles, respect for persons, beneficence, and justice, that govern all research involving human participants. It was written in response to the Tuskegee Syphilis Study. It created the philosophical foundation for all subsequent human subjects research regulations in the United States and, through its influence on ICH GCP, worldwide. It also clarified the crucial distinction between medical practice and medical research, which remains central to Good Clinical Practice training today.
What is the purpose of the Belmont Report (1979)?
The purpose of the 1979 Belmont Report was to identify the basic ethical principles underlying all biomedical and behavioral research involving human subjects, and to develop guidelines ensuring that research was conducted in accordance with those principles. It was created by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, established by the US National Research Act of 1974, itself a direct response to the Tuskegee scandal. The Belmont Report’s purpose was both retrospective (to explain why Tuskegee was wrong) and prospective (to prevent it from happening again).
How does the Declaration of Helsinki connect to ICH GCP?
ICH GCP E6 (R3) explicitly states in its first principle that clinical trials shall be conducted in accordance with the ethical principles originating in the Declaration of Helsinki. This means that every GCP requirement, from sponsor oversight to investigator obligations to informed consent procedures, is ethically grounded in the Declaration of Helsinki. Understanding the Declaration is therefore essential for anyone preparing for a Good Clinical Practice certification or conducting GCP-compliant clinical research.
Is the Declaration of Helsinki legally binding?
No. The Declaration of Helsinki is not a legally binding international instrument. However, its principles are incorporated by reference into national regulations, ICH GCP guidelines, and institutional review board standards across more than 60 countries, giving it regulatory force in practice. Investigators who conduct clinical trials intended for regulatory submission are effectively obligated to follow the Declaration’s principles through the requirements of ICH GCP E6 R3.
What is the Nuremberg Code's connection to the Declaration of Helsinki?
The Declaration of Helsinki was directly inspired by the Nuremberg Code of 1947, which was the first international ethical framework for human research, produced in response to Nazi medical experiments. Where the Nuremberg Code focused on voluntary consent as the absolute foundation of ethical research, the Declaration of Helsinki built on this to create a more comprehensive framework addressing the specific context of physician-investigators, ethics committee review, and the balance between individual and societal benefits. The historical thread runs from Nuremberg (1947) → Declaration of Helsinki (1964, revised through 2024) → Belmont Report (1979) → ICH GCP (1996, revised through E6 R3, 2025).
How do I start a career in clinical data management?
Start by completing an ICH GCP E6(R3) training certification, learning an EDC platform, familiarizing yourself with CDISC standards, and applying for entry-level roles such as Clinical Data Associate at a CRO or pharmaceutical company. Pursuing the SCDM’s CCDM certification once you have two or more years of experience is the next important career milestone.
References
- World Medical Association (WMA) – Declaration of Helsinki 2024
- WMA News Post on Revised Declaration of Helsinki
- Declaration of Helsinki: Full paragraph-by-paragraph comparison: version 2024 vs. 2013
- US HHS Office for Human Research Protections – The Belmont Report (1979)
- Nagai et al. (2022) – The creation of the Belmont Report and its effect on ethical principles: a historical study – PMC / NIH
- PharmaEduCenter – The Belmont Report: 3 essential principles behind every clinical trial
- PharmaEduCenter – What’s new in ICH GCP E6 R3?
